Serum Receptor Activator of Nuclear Factor-κ B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients

被引:6
|
作者
Rashtchizadeh, Nadereh [2 ]
Ghorbanihaghjo, Amir [1 ]
Argani, Hassan [2 ]
Meimand, Saeed Mahmoudi [2 ]
Safa, Javid [2 ]
Vatankhahan, Hamidreza [2 ]
Shahidi, Maryam [2 ]
机构
[1] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran
[2] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran
关键词
Hemodialysis; Kidney transplanted patients; Osteoprotegrin; Serum receptor activator of nuclear factor-kappa B ligand; VASCULAR CALCIFICATION; BONE-RESORPTION; DISEASE; OSTEOCLASTOGENESIS; ATHEROSCLEROSIS; EXPRESSION; MARKERS; RATS; OPG;
D O I
10.1111/j.1744-9987.2012.01097.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum receptor activator of nuclear factor-? B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor-? B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age-matched renal transplant patients. Osteoprotegrin (P = 0.001) and intact parathyroid hormone (P = 0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r = 0.88, P = 0.001 and r = 0.34, P = 0.02, respectively) and renal transplant patients (r = 0.92, P = 0.001 and r = 0.46, P = 0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure.
引用
收藏
页码:600 / 604
页数:5
相关论文
共 50 条
  • [21] Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
    Trouvin, Anne-Priscille
    Goeb, Vincent
    CLINICAL INTERVENTIONS IN AGING, 2010, 5 : 345 - 354
  • [22] Targeting the receptor activator of nuclear factor-κB (RANK) ligand in prostate cancer bone metastases
    Saad, Fred
    Markus, Richard
    Goessl, Carsten
    BJU INTERNATIONAL, 2008, 101 (09) : 1071 - 1075
  • [23] Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy
    Todenhoefer, Tilman
    Hennenlotter, Joerg
    Leidenberger, Philipp
    Wald, Alexander
    Hohneder, Andrea
    Kuehs, Ursula
    Mischinger, Johannes
    Aufderklamm, Stefan
    Gakis, Georgios
    Blumenstock, Gunnar
    Stenzl, Arnulf
    Schwentner, Christian
    BJU INTERNATIONAL, 2014, 113 (01) : 152 - 159
  • [24] Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization
    Jiang, Min
    Peng, Lei
    Yang, Kai
    Wang, Tianqi
    Yan, Xueming
    Jiang, Tao
    Xu, Jianrong
    Qi, Jin
    Zhou, Hanbing
    Qian, Niandong
    Zhou, Qi
    Chen, Bo
    Xu, Xing
    Deng, Lianfu
    Yang, Chunhao
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (11) : 5370 - 5381
  • [25] Differential expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin mRNA in periodontal diseases
    Bostanci, N.
    Ilgenli, T.
    Emingil, G.
    Afacan, B.
    Han, B.
    Toz, H.
    Berdeli, A.
    Atilla, G.
    McKay, I. J.
    Hughes, F. J.
    Belibasakis, G. N.
    JOURNAL OF PERIODONTAL RESEARCH, 2007, 42 (04) : 287 - 293
  • [26] Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand
    Wang, Qing-Ping
    Yang, Li
    Li, Xian-Ping
    Xie, Hui
    Liao, Er-Yuan
    Wang, Min
    Luo, Xiang-Hang
    BONE, 2012, 51 (03) : 515 - 523
  • [27] Cetylpyridinium Chloride Inhibits Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclast Formation
    Zheng, Ting
    Chen, Ling
    Noh, A. Long Sae Mi
    Yim, Mijung
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (04) : 509 - 514
  • [28] Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis
    Balli, Umut
    Aydogdu, Ahmet
    Dede, Figen Ongoz
    Turer, Cigdem Coskun
    Guven, Berrak
    JOURNAL OF PERIODONTOLOGY, 2015, 86 (12) : 1396 - 1404
  • [29] Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency
    Witkowska-Sedek, Ewelina
    Ruminska, Malgorzata
    Stelmaszczyk-Emmel, Anna
    Sobol, Maria
    Demkow, Urszula
    Pyrzak, Beata
    CLINICAL MEDICINE RESEARCH, 2018, 1116 : 63 - 73
  • [30] Miconazole inhibits receptor activator of nuclear factor-κB ligand-mediated osteoclast formation and function
    Zheng, Ting
    Wang, Xin
    Yim, Mijung
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 737 : 185 - 193